A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
Clinical trial NCT03674177 · COMPLETED
Trial details
- NCT number
- NCT03674177
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-30
- Primary completion
- 2019-04-16
- Enrollment
- 502
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.